CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $1.45B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.07: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.71BCNY1.45B · vs all stocks (USD)
Trailing P/E
117.67xRevenue (TTM)
549.11MCNY82.00M · vs all stocks (USD)
Profit Margin
13.12%Beta
-0.2640xvs all stocks
52-Week Change
2.92%vs all stocks
Market Capitalization
9.71BCNY1.45B · vs all stocks (USD)
Enterprise Value
8.45BCNY1.26B · vs all stocks (USD)
Trailing P/E
117.67xPrice to Sales (TTM)
17.69xPrice to Book (MRQ)
7.23xEnterprise to Revenue
15.38xEnterprise to EBITDA
92.79xGross Margin
17.62%Profit Margin
13.12%Operating Margin
7.19%Return on Assets (TTM)
-0.66%Return on Equity (TTM)
6.34%Revenue (TTM)
549.11MCNY82.00M · vs all stocks (USD)
Revenue per Share (TTM)
0.2010CNYUpdated Sep 21, 2026Quarterly Revenue Growth
51.00%Gross Profit (TTM)
69.99MCNY10.45M · vs all stocks (USD)
EBITDA (TTM)
424.73MCNY63.42M · vs all stocks (USD)
Net Income (TTM)
72.03MCNY10.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-97.50%Operating Cash Flow (TTM)
74.10MCNY11.07M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-106.50MCNY-15.90M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
22.36MCNYFY2025 · Dec 31, 2025Revenue
465.12MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
398.58MCNYFY2025 · Dec 31, 2025Gross Profit
66.55MCNYFY2025 · Dec 31, 2025Operating Income
-38.09MCNY-5.69M · vs all stocks (USD)
Pre-tax Income
169.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
36.41MCNYFY2025 · Dec 31, 2025Net Income
132.69MCNYFY2025 · Dec 31, 2025EBIT
174.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
424.73MCNYFY2025 · Dec 31, 2025Research & Development
24.47MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
27.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
5.61MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0519CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0519CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.72BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.72BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
132.69MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.70MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
331.89MCNYFY2025 · Dec 31, 2025Free Cash Flow
330.51MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
319.51MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
132.69MCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.59MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
32.81MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
155.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
1.38MCNYFY2025 · Dec 31, 2025Net Acquisitions
1.39KCNYFY2025 · Dec 31, 2025Purchase of Investments
-23.00MCNYFY2025 · Dec 31, 2025Sale of Investments
10.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-11.58MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
144.15MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-20.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-507.89KCNYFY2025 · Dec 31, 2025Other Financing Charges
52.46MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
176.11MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.75BSharesUpdated Sep 21, 2026Float Shares
1.49BSharesUpdated Sep 21, 2026% Held by Insiders
29.28%vs all stocks
% Held by Institutions
2.62%vs all stocks
Total Cash (MRQ)
200.37MCNY29.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0880CNYUpdated Sep 21, 2026Total Debt (MRQ)
538.46MCNY80.41M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4699xCurrent Ratio (MRQ)
1.32xBook Value per Share (MRQ)
0.4880CNYUpdated Sep 21, 2026Total Assets
2.14BCNY318.88M · vs all stocks (USD)
Total Current Assets
705.91MCNYFY2025 · Dec 31, 2025Total Liabilities
1.11BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.43BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
622.23MCNYFY2025 · Dec 31, 2025Total Current Liabilities
491.08MCNYFY2025 · Dec 31, 2025Cash
319.51MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.01MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
320.52MCNYFY2025 · Dec 31, 2025Accounts Receivable
157.62MCNYFY2025 · Dec 31, 2025Inventory
40.42MCNYFY2025 · Dec 31, 2025Accounts Payable
48.10MCNYFY2025 · Dec 31, 2025Short-term Debt
213.89MCNYFY2025 · Dec 31, 2025Other Current Liabilities
44.71MCNYFY2025 · Dec 31, 2025Long-term Debt
364.70MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
20.12MCNYFY2025 · Dec 31, 2025Common Stock (Book)
2.28BCNYFY2025 · Dec 31, 2025Retained Earnings
-2.70BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.02BCNY152.63M · vs all stocks (USD)
Treasury Stock
42.68MCNYFY2025 · Dec 31, 202552-Week Low
2.81CNYUpdated Sep 21, 202652-Week High
7.57CNYUpdated Sep 21, 202652-Week Change
2.92%vs all stocks
Beta
-0.2640xvs all stocks
50-Day MA
3.52CNYUpdated Sep 21, 2026200-Day MA
4.26CNYUpdated Sep 21, 2026Avg 10-Day Volume
129.61MSharesUpdated Sep 21, 2026Avg 30-Day Volume
113.05MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.0300CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.07: safe zoneNotable
Altman Z-Score: 4.07
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $1.45B, above the global median of $1.18BNotable
Market cap (USD): 1,450,315,419.232Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Traditional Chinese Medicine Holdings Co. Limited
Tier 1ProductionApproval-Gated PipelineFlowInterface
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow